Aligning Science Across Parkinson's Logo Text
Submit site search
  • LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration

    By on

    Background Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent cause of familial Parkinson’s disease (PD). The incomplete penetrance of LRRK2 mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. Methods and Results We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide, and we performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, macrophage/monocyte brain infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines, increased CD4+ T-cell infiltration and α-synuclein aggregation in the colon. Interestingly, peripheral immune activation and colonic α-synuclein aggregation precede astro-/microgliosis and neurodegeneration. Conclusions Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.

  • Striatal dopamine measurement through HPLC

    By on

    Protocol for striatal dopamine measurement in mouse brain

  • Stereotaxic Injections

    By on

    Stereotaxic injections for Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain.

  • Code for integrated multi-cohort analysis of the Parkinson’s disease gut metagenome

    By on

    Detailed scripts to reproduce all analysis and data visualization for the paper "Integrated multi-cohort analysis of the Parkinson's disease gut metagenome."

  • Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures–Gene Validation FCS

    By on

    FCS files corresponding to the gene validation experiment described in "Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures"

  • Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures–Cell Surface FCS

    By on

    FCS files corresponding to the cell surface experiment described in "Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures"

  • Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease

    By on

    Border-associated macrophages (BAMs) are crucial in Parkinson's disease pathogenesis by initiating neuroinflammation, highlighting a potential target for therapeutic intervention.

  • Unaltered T cell responses to common antigens in individuals with Parkinson’s disease

    By on

    T cells have been shown to be overactive in individuals with PD. The authors tested a wide variety of commonly encountered immune targets on PD and non-PD control derived T cells and observed no differences between their immune responses.

  • Mitochondrial Antigen Presentation in RAW macrophages

    By on

    This protocol details methods for 3-day Mitochondrial Antigen Presentation Assay in a murine macrophage cell line (RAW) that expresses a glycoprotein B (gB) of herpes simplex virus 1 (HSV1) targeted to the mitochondrial matrix (mito-gB). A gB-specific CD8+ T cell hybridoma recognizing the gB498–505peptide loaded on MHC class I molecules is also used to monitor antigen presentation through a beta-galactosidase assay kit.

  • Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes

    By on

    Review: This review focuses on the endolysosomal pathway roles of GBA and LRRK2, highlighting the role and activity of Rab GTPases as LRRK2 substrates.

  • (x6) GBA heterozygous and homozygous mutant fibroblast lines available to share

    By on

    Cell lines deposited at ATCC used in a publication (10.1093/hmg/ddac233) include UCL-CTRL001, UCL-CTRL002, UCL-CTRL003, UCL-YCTRL001, UCL-E001K, UCL-N001S, and UCL-N002S, each with specific RRIDs.

  • Fecal metagenomic sequencing data for PD patients and controls from the BioCollective

    By on

    Fecal metagenomic sequencing data associated with Boktor et al. (2023). This dataset includes samples from the BioCollective cohort.

  • Bile acids and neurological disease

    By on

    This review will focus on how bile acids are being used in clinical trials to treat neurological diseases due to their central involvement with the gut-liver-brain axis and their physiological and pathophysiological roles in both normal brain function and multiple neurological diseases. The synthesis of primary and secondary bile acids species and how the regulation of the bile acid pool may differ between the gut and brain is discussed. The expression of several bile acid receptors in brain and their currently known functions along with the tools available to manipulate them pharmacologically are examined, together with discussion of the interaction of bile acids with the gut microbiome and their lesser-known effects upon brain glucose and lipid metabolism. How dysregulation of the gut microbiome, aging and sex differences may lead to disruption of bile acid signalling and possible causal roles in a number of neurological disorders are also considered. Finally, we discuss how pharmacological treatments targeting bile acid receptors are currently being tested in an array of clinical trials for several different neurodegenerative diseases

  • Measurement of GLP-1 release in cell supernatant from Hutu-80 enteroendocrine cells via ELISA

    By on

    Measurement of GLP-1 release in cell supernatant from Hutu-80 enteroendocrine cells via ELISA

  • Protocols for “Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice”.

    By on

    This is a collection of protocols associated to the manuscript "Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice".

  • Western blot – alpha-synuclein

    By on

    This protocol describes how to detect alpha-synuclein in protein derived from STC-1 cells by western blot using DAB/peroxidase or ECL to visualize the bands.

  • Alpha-synuclein immunochemistry on STC-1 cells using DAB

    By on

    This protocol describes how to visualise alpha-synuclein in STC-1 cells by DAB immunohistochemistry. It also works for other antibodies (e.g. 5-HT, CCK, GLP).

  • Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK

    By on

    Activating V600E in v-Raf murine sarcoma viral oncogene homolog B (BRAF) is a common driver mutation in cancers of multiple tissue origins, including melanoma and glioma. BRAFV600E has also been implicated in neurodegeneration. The present study aims to characterize BRAFV600E during cell death and proliferation of three major cell types of the central nervous system: neurons, astrocytes, and microglia. Multiple primary cultures (primary cortical mixed culture) and cell lines of glial cells (BV2) and neurons (SH-SY5Y) were employed. BRAFV600E and BRAFWT expression was mediated by lentivirus or retrovirus. Blockage of downstream effectors (extracellular signal-regulated kinase 1/2 and JNK1/2) were achieved by siRNA. In astrocytes and microglia, BRAFV600E induces cell proliferation, and the proliferative effect in microglia is mediated by activated extracellular signal-regulated kinase, but not c-Jun N-terminal kinase. Conditioned medium from BRAFV600E-expressing microglia induced neuronal death. In neuronal cells, BRAFV600E directly induces neuronal death, through c-Jun N-terminal kinase but not extracellular signal-regulated kinase. We further show that BRAF-related genes are enriched in pathways in patients with Parkinson's disease. Our study identifies distinct consequences mediated by distinct downstream effectors in dividing glial cells and in neurons following the same BRAF mutational activation and a causal link between BRAF-activated microglia and neuronal cell death that does not require physical proximity. It provides insight into a possibly important role of BRAF in neurodegeneration as a result of either dysregulated BRAF in neurons or its impact on glial cells.

  • Cell viability assessment

    By on

    This is the protocol for assessing cell viability using a MTS cell proliferation assay kit.

  • Midbrain-like Organoids generation from hiPSCs

    By on

    Protocol for generating midbrain organoids from human iPSCs.

Load More
Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.